Allergy Therapeutics plc (LON:AGY – Get Free Report) shares dropped 0.9% during trading on Monday . The stock traded as low as GBX 5.25 ($0.07) and last traded at GBX 5.25 ($0.07). Approximately 557,008 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 729,353 shares. The stock had previously closed at GBX 5.30 ($0.07).
Allergy Therapeutics Stock Down 0.9 %
The firm has a market capitalization of £250.43 million, a price-to-earnings ratio of -88.33, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22. The firm has a fifty day moving average price of GBX 4.53 and a 200 day moving average price of GBX 4.37.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Technology Stocks Explained: Here’s What to Know About Tech
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Dividend Capture Strategy: What You Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
